Trading Advice for Novo Nordisk A/s NVO including day trading swing trading and long term investing plans for NVO ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other injected diabetes medications such as Ozempic. Read more.

Novo Nordisk (NVO) has released an update. Novo Nordisk has disclosed recent transactions involving the purchase of 1,300 American Depositary Receipts (ADRs) by its board members and executives. This ...

Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.

(Reuters) - Shares of Hims & Hers Health slumped 15% on Thursday after Amazon.com (NASDAQ: AMZN) launched a rival service ...

Hims & Hers Health Inc. shares tumbled 22% Thursday, on concerns that Amazon.com Inc.'s latest push into healthcare will disrupt Hims & Hers' business.

"We have seen an alarming rise in diabetes over the past three decades, which reflects the increase in obesity, compounded by the impacts of the marketing of unhealthy food, a lack of physical ...

Pentagon officials did their best to downplay the incident, and the US Navy didn't bother to investigate, but the "Tic Tac" ...

A recent study that found there has been a massive increase in type 2 diabetes cases worldwide since 1990 is an indication ...

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

Novo Nordisk is ceasing production of human insulin pens, focusing on newer obesity and diabetes injections. This shift has ...